Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp

ClinicalTrials.gov ID: NCT03123471

Public ClinicalTrials.gov record NCT03123471. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis of the scalp. Approximately 300 subjects with moderate to severe plaque psoriasis of the scalp will be randomized 2:1 to receive either apremilast 30 mg twice daily (BID) or placebo for the first 16 weeks.

Study identification

NCT ID
NCT03123471
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Amgen
Industry
Enrollment
303 participants

Conditions and interventions

Conditions

Interventions

Drug · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 15, 2017
Primary completion
Aug 12, 2018
Completion
Jan 8, 2019
Last update posted
May 12, 2020

2017 – 2019

United States locations

U.S. sites
32
U.S. states
20
U.S. cities
29
Facility City State ZIP Site status
Northwest Arkansas Clinical Trials Center, PLLC / Hull Dermatology Rogers Arkansas 72758
Tien Q. Nguyen MD Inc Fountain Valley California 92708
Dermatology Research Associates Los Angeles California 90045
San Luis Dermatology and Laser Clinic San Luis Obispo California 93405
University of Connecticut Farmington Connecticut 06030
Florida Academic Centers Research and Education Coral Gables Florida 33134
International Dermatology Research Miami Florida 33144
Renstar Medical Research Ocala Florida 34470
Dermatologic Surgery Specialists, P.C. Macon Georgia 31217
MedaPhase INC Newnan Georgia 30263
The Indiana Clinical Trials Center, PC Plainfield Indiana 46168
DS Research Louisville Kentucky 40202
DS Research Louisville Kentucky 40241
Dermatology and Advanced Aesthetics Lake Charles Louisiana 70605
Lawrence Green, MD, LLC Rockville Maryland 20850
Central Dermatology St Louis Missouri 63117
Skin Specialists, PC Omaha Nebraska 68144
Psoriasis Treatment Center of Central New Jersey East Windsor New Jersey 08520
SUNY Downstate Medical Center Brooklyn New York 11203
Forest Hills Dermatology Group Forest Hills New York 11375
Icahn School of Medicine at Mount Sinai Medical Center New York New York 10029
Sadick Research Group New York New York 10075
Wake Forest University Health Sciences Winston-Salem North Carolina 27104
Wright State Physicians Fairborn Ohio 45324
University of Pittsburgh Medical Center Pittsburgh Pennsylvania 15213
Austin Dermatology Associates Austin Texas 78705
Modern Research Associates PLLC Dallas Texas 75231
Center for Clinical Studies Webster Texas 77598
University of Utah Salt Lake City Utah 84107
Virginia Clinical Research Inc Norfolk Virginia 23502
Eastern Virginia Medical School Norfolk Virginia 23507
Medical College of Wisconsin Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03123471, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 12, 2020 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03123471 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →